



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Caerdydd a'r Fro
Cardiff and Vale
University Health Board

Freedom of Information Act 2000 - Request Reference FoI/21/481
Treatment of Breast Cancer

Information Requested:

I am interested in understanding how breast cancer is treated by your trust, specifically around the usage of systemic anti-cancer therapies. Could you please help by providing the patient numbers that I have requested below:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?

- Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent
- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- Atezolizumab + Nab-paclitaxel/Paclitaxel
- Capecitabine as a single agent
- Carboplatin or Cisplatin as a single agent
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fluorouracil
- Fulvestrant as a single agent
- Goserelin
- Lapatinib
- Neratinib
- Olaparib
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Pertuzumab + Trastuzumab + Docetaxel
- Platinum (e.g. carboplatin or cisplatin) as a single agent
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Talazoparib
- Tamoxifen
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab as a single agent
- Trastuzumab emtansine
- Trastuzumab deruxtecan
- Any other active systemic anti-cancer therapy

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?





GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Caerdydd a'r Fro
Cardiff and Vale
University Health Board

Response Details:

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

However, under our Section 16 obligation to provide advice and assistance I can inform you of the patient numbers treated for ANY condition with the below medications:

| | |
|---------------------------|----|
| CARBOPLATIN INJECTION | 10 |
| CISPLATIN | 8 |
| DOCETAXEL | 1 |
| DOXORUBICIN HYDROCHLORIDE | 30 |
| DOXORUBICIN | 11 |
| EVEROLIMUS | 1 |
| EXEMESTANE | 2 |
| LETROZOLE | 21 |
| TAMOXIFEN | 5 |

